Gurcan Gunaydin, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Somatic Hypermutation, Immunoglobulin | 1 | 2022 | 100 | 0.820 |
Why?
|
| Cytidine Deaminase | 1 | 2022 | 247 | 0.730 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2022 | 257 | 0.690 |
Why?
|
| Laryngeal Neoplasms | 1 | 2023 | 511 | 0.660 |
Why?
|
| Chemokine CCL2 | 2 | 2019 | 595 | 0.490 |
Why?
|
| Singlet Oxygen | 3 | 2020 | 54 | 0.470 |
Why?
|
| Carcinoma | 1 | 2023 | 2344 | 0.380 |
Why?
|
| Gynecomastia | 1 | 2011 | 86 | 0.370 |
Why?
|
| Photosensitizing Agents | 4 | 2020 | 604 | 0.370 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 219 | 0.340 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2018 | 930 | 0.330 |
Why?
|
| Photochemotherapy | 3 | 2020 | 807 | 0.310 |
Why?
|
| Cell Hypoxia | 2 | 2020 | 659 | 0.300 |
Why?
|
| Cell Communication | 1 | 2013 | 1628 | 0.260 |
Why?
|
| Neoplastic Stem Cells | 1 | 2013 | 1341 | 0.240 |
Why?
|
| Organ Preservation Solutions | 1 | 2024 | 93 | 0.230 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2024 | 589 | 0.220 |
Why?
|
| Isoleucine | 1 | 2022 | 111 | 0.210 |
Why?
|
| Fibroblasts | 1 | 2013 | 4036 | 0.210 |
Why?
|
| Liver Transplantation | 2 | 2024 | 2203 | 0.200 |
Why?
|
| Friends | 1 | 2022 | 147 | 0.200 |
Why?
|
| Liver Regeneration | 1 | 2023 | 213 | 0.190 |
Why?
|
| Osteopontin | 1 | 2023 | 296 | 0.190 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2023 | 414 | 0.190 |
Why?
|
| Immunoglobulin Class Switching | 1 | 2022 | 290 | 0.190 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2023 | 534 | 0.180 |
Why?
|
| Organoselenium Compounds | 1 | 2019 | 21 | 0.180 |
Why?
|
| Boron Compounds | 1 | 2019 | 170 | 0.160 |
Why?
|
| Fatty Liver | 1 | 2024 | 743 | 0.150 |
Why?
|
| Monocytes | 2 | 2019 | 2544 | 0.150 |
Why?
|
| Reperfusion Injury | 1 | 2024 | 1004 | 0.150 |
Why?
|
| Chemokine CXCL12 | 1 | 2019 | 450 | 0.140 |
Why?
|
| Cells | 1 | 2018 | 164 | 0.140 |
Why?
|
| Metformin | 1 | 2024 | 875 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2023 | 3460 | 0.120 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2015 | 124 | 0.120 |
Why?
|
| Breast Neoplasms | 3 | 2019 | 20750 | 0.110 |
Why?
|
| Neoplasms | 1 | 2022 | 21688 | 0.110 |
Why?
|
| Granulocytes | 1 | 2015 | 551 | 0.110 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3694 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2015 | 800 | 0.090 |
Why?
|
| Light | 1 | 2016 | 1334 | 0.090 |
Why?
|
| Living Donors | 2 | 2024 | 612 | 0.080 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2022 | 3011 | 0.080 |
Why?
|
| Breast Diseases | 1 | 2011 | 443 | 0.080 |
Why?
|
| Hyperplasia | 1 | 2011 | 1153 | 0.080 |
Why?
|
| Cell Proliferation | 5 | 2023 | 10300 | 0.070 |
Why?
|
| Mitochondria | 1 | 2019 | 3523 | 0.070 |
Why?
|
| Melanoma | 1 | 2023 | 5569 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2023 | 9170 | 0.060 |
Why?
|
| Raffinose | 1 | 2024 | 49 | 0.060 |
Why?
|
| Humans | 13 | 2024 | 746044 | 0.060 |
Why?
|
| Mastectomy | 1 | 2011 | 1816 | 0.050 |
Why?
|
| Allopurinol | 1 | 2024 | 186 | 0.050 |
Why?
|
| Endostatins | 1 | 2023 | 167 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2023 | 280 | 0.050 |
Why?
|
| Cell Survival | 2 | 2023 | 5761 | 0.050 |
Why?
|
| Glutathione | 1 | 2024 | 565 | 0.050 |
Why?
|
| Cohort Studies | 1 | 2023 | 40503 | 0.040 |
Why?
|
| Adenosine | 1 | 2024 | 819 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 53218 | 0.040 |
Why?
|
| NIH 3T3 Cells | 1 | 2019 | 671 | 0.040 |
Why?
|
| Photochemistry | 1 | 2018 | 238 | 0.040 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2019 | 720 | 0.040 |
Why?
|
| Phosphatidylserines | 1 | 2018 | 188 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 635 | 0.030 |
Why?
|
| Antineoplastic Agents | 1 | 2019 | 13538 | 0.030 |
Why?
|
| Interleukin-12 | 1 | 2019 | 577 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2011 | 12839 | 0.030 |
Why?
|
| Macrophage Activation | 1 | 2019 | 547 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2018 | 5835 | 0.030 |
Why?
|
| Animals | 5 | 2024 | 166331 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2019 | 1877 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2018 | 4296 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2019 | 725 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 3077 | 0.030 |
Why?
|
| Zinc | 1 | 2018 | 683 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2019 | 1156 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2019 | 3077 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2018 | 1302 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 1853 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 38752 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2015 | 973 | 0.020 |
Why?
|
| Insulin | 1 | 2024 | 6470 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 2015 | 1415 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2018 | 3687 | 0.020 |
Why?
|
| Liver | 1 | 2024 | 7370 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 10718 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2023 | 16657 | 0.020 |
Why?
|
| Cell Movement | 1 | 2019 | 5162 | 0.020 |
Why?
|
| Rats | 1 | 2023 | 23680 | 0.020 |
Why?
|
| Young Adult | 1 | 2011 | 57106 | 0.020 |
Why?
|
| Mice | 2 | 2024 | 80087 | 0.020 |
Why?
|
| Female | 4 | 2019 | 382109 | 0.010 |
Why?
|
| Macrophages | 1 | 2019 | 5652 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2015 | 8125 | 0.010 |
Why?
|
| Cell Line | 1 | 2018 | 15631 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 8355 | 0.010 |
Why?
|
| Apoptosis | 1 | 2018 | 9421 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2019 | 11384 | 0.010 |
Why?
|
| Male | 2 | 2024 | 351093 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2015 | 18891 | 0.010 |
Why?
|